An investigative study of pancreatic exocrine biomarkers, histology, and histomorphometry in male Zucker Diabetic Fatty (ZDF) rats given dulaglutide by subcutaneous injection twice weekly for 13 weeks

Toxicologic Pathology

Volumn 43, Issue 8, 2015, Pages 1093-1102

  Usborne, Amy ^a   Byrd, Richard A ^a   Meehan, James ^b   Blackbourne, Jamie L ^a   Sullivan, John ^a   Poitout Belissent, Florence ^b   Prefontaine, Annick ^b   Martin, Jennifer A ^a   Vahle, John L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

dulaglutide; GLP 1; pancreas; rat

Indexed keywords

ALPHA AMYLASE PANCREAS ISOENZYME; AMYLASE; BIOLOGICAL MARKER; CREATININE; DULAGLUTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; KI 67 ANTIGEN; TRIACYLGLYCEROL LIPASE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

AMYLASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ATROPHY; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFECT; ENZYME ACTIVITY; EXPERIMENTAL DIABETES MELLITUS; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; INCIDENCE; INSULIN BLOOD LEVEL; KIDNEY HYPERTROPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MORPHOMETRICS; NONHUMAN; PANCREAS INJURY; PANCREAS ISLET CELL HYPERPLASIA; PANCREAS SECRETION; PANCREATITIS; PRIORITY JOURNAL; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANALYSIS; ANIMAL; BODY WEIGHT; DRUG EFFECTS; HUMAN; METABOLISM; PANCREAS; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; ZUCKER RAT;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, SUBCUTANEOUS; MALE; PANCREAS; RATS; RATS, ZUCKER; RECOMBINANT FUSION PROTEINS;

EID: 84948706105     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623315596857     Document Type: Article

References (47)

1. Ahmad S. R., Swann J., (2008). Exenatide and rare adverse events. N Engl J Med 358, 1970-71; discussion 1971-1972.
2. Ayoub W. A., Kumar A. A., Naguib H. S., Taylor H. C., (2010). Exenatide-induced acute pancreatitis. Endocr Pract 16, 80-83.
3. Baggio L. L., Drucker D. J., (2007). Biology of incretins: Glp-1 and Gip. Gastroenterology 132, 2131-57.
4. Butler A. E., Galasso R., Matveyenko A., Rizza R. A., Dry S., Butler P. C., (2010). Pancreatic duct replication is increased with obesity and type 2 diabetes in humans. Diabetologia 53, 21-26.
5. Chadwick K. D., Fletcher A. M., Parrula M. C., Bonner-Weir S., Mangipudy R. S., Janovitz E., Graziano M. J., Roy D., Reilly T. P., (2013). Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: A potential confounding factor in the nonclinical assessment of glucagon-like peptide (Glp)-1-based therapies. Diabetes 63, 1303-13.
6. Cure P., Pileggi A., Alejandro R., (2008). Exenatide and rare adverse events. N Engl J Med 358, 1969-70; discussion 1971-1962.
7. Denker P. S., Dimarco P. E., (2006). Exenatide (exendin-4)-induced pancreatitis: A case report. Diabetes Care 29, 471.
8. Dore D. D., Bloomgren G. L., Wenten M., Hoffman C., Clifford C. R., Quinn S. G., Braun D. K., Noel R. A., Seeger J. D., (2011). A Cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13, 559-66.
9. Dore D. D., Seeger J. D., Arnold Chan K., (2009). Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25, 1019-27.
10. Drucker D. J., (2006). The biology of incretin hormones. Cell Metab 3, 153-65.
11. Egan A. G., Blind E., Dunder K., de Graeff P. A., Hummer B. T., Bourcier T., Rosebraugh C., (2014). Pancreatic safety of incretin-based drugs-Fda and Ema assessment. N Engl J Med 370, 794-97.
12. Eustis S., Boorman G., Hayashi Y., (1990). The exocrine pancreas. In Pathology of the Fischer Rat (Boorman G. A., Eustis S., Ewell M., Montgomery C., MacKenzie M., eds.), pp. 95-108. Academic Press, New York.
13. Evans H. E., Christensen G. C., (1979). The digestive apparatus and abdomen. In Miller's Anatomy of the Dog (Miller Malcolm E., Howard E Evans, Christensen George C,.), pp. 411-506. W.B. Saunders Company, Philadelphia, PA.
14. Food and Drug Administration. (2014). Trulicity: Pharmacology review. Accessed April 14, 2015. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/125469Orig1s000PharmR.pdf. p 181.
15. Frossard J. L., Steer M. L., Pastor C. M., (2008). Acute pancreatitis. Lancet 371, 143-52.
16. Garg R., Chen W., Pendergrass M., (2010). Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: A retrospective observational pharmacy claims analysis. Diabetes Care 33, 2349-54.
17. Geldof A. A., Becking J. L., de Vries C. D., van der Veen E. A., (1992). Histopathological changes in rat pancreas after fasting and cassava feeding. In vivo 6, 545-51.
18. Gier B., Matveyenko A. V., Kirakossian D., Dawson D., Dry S. M., Butler P. C., (2012). Chronic Glp-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras (G12d) mouse model. Diabetes 61, 1250-62.
19. Girman C. J., Kou T. D., Cai B., Alexander C. M., O'Neill E. A., Williams-Herman D. E., Katz L., (2010). Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab 12, 766-71.
20. Gotthardt M., Fischer M., Naeher I., Holz J. B., Jungclas H., Fritsch H. W., Behe M., Goke B., Joseph K., Behr T. M., (2002). Use of the incretin hormone glucagon-like peptide-1 (Glp-1) for the detection of insulinomas: Initial experimental results. Eur J Nucl Med Mol Imaging 29, 597-606.
21. Grigoropoulou P., Eleftheriadou I., Zoupas C., Diamanti-Kandarakis E., Tentolouris N., (2013). Incretin-based therapies for type 2 diabetes mellitus: Effects on insulin resistance. Curr Diab Rev 9, 412-17.
22. Holst J. J., Vilsboll T., Deacon C. F., (2009). The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol 297, 127-36.
23. Iyer S. N., Drake A. J. 3rd, West R. L., Mendez C. E., Tanenberg R. J., (2012). Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide. Endocr Pract 18, e10-13.
24. Keller J., Layer P., (2005). Human pancreatic exocrine response to nutrients in health and disease. Gut 54, vi1-28.
25. Koehler J. A., Baggio L. L., Lamont B. J., Ali S., Drucker D. J., (2009). Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice. Diabetes 58, 2148-61.
26. Li X., Zhang L., Meshinchi S., Dias-Leme C., Raffin D., Johnson J. D., Treutelaar M. K., Burant C. F., (2006). Islet microvasculature in islet hyperplasia and failure in a model of type 2 diabetes. Diabetes 55, 2965-73.
27. Macconell L., Brown C., Gurney K., Han J., (2012). Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: Integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 5, 29-41.
28. Matveyenko A. V., Dry S., Cox H. I., Moshtaghian A., Gurlo T., Galasso R., Butler A. E., Butler P. C., (2009). Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: Interactions with metformin. Diabetes 58, 1604-15.
29. Nachnani J. S., Bulchandani D. G., Nookala A., Herndon B., Molteni A., Pandya P., Taylor R., Quinn T., Weide L., Alba L. M., (2010). Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia 53, 153-59.
30. Noel R. A., Braun D. K., Patterson R. E., Bloomgren G. L., (2009). Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective Cohort study. Diabetes Care 32, 834-38.
31. Nyborg N. C., Molck A. M., Madsen L. W., Knudsen L. B., (2012). The human Glp-1 analog liraglutide and the pancreas: Evidence for the absence of structural pancreatic changes in three species. Diabetes 61, 1243-49.
32. Pyke C., Heller R. S., Kirk R. K., Orskov C., Reedtz-Runge S., Kaastrup P., Hvelplund A., Bardram L., Calatayud D., Knudsen L. B., (2014). Glp-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155, 1280-90.
33. Richards C., Fitzgerald P., Carol B., Rosenstock L., Lipkin L., (1964). Segmental division of the rat pancreas for experimental procedures. Lab Invest 13, 1303-21.
34. Sandhyamani S., Vijayakumari A., Balaraman Nair M., (1999). Bonnet monkey model for pancreatic changes in induced malnutrition. Pancreas 18, 84-95.
35. Shackelford C., Long G., Wolf J., Okerberg C., Herbert R., (2002). Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 30, 93-96.
36. Shiota M., Printz R. L., (2012). Animal Models of Diabetes Research. Humana Press, New York.
37. Singh S., Chang H. Y., Richards T. M., Weiner J. P., Clark J. M., Segal J. B., (2013). Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched case-control study. JAMA Intern Med 173, 534-39.
38. Smith P. A., Sunter J. P., Case R. M., (1982). Progressive atrophy of pancreatic acinar tissue in rats fed a copper-deficient diet supplemented with d -penicillamine or triethylene tetramine: Morphological and physiological studies. Digestion 23, 16-30.
39. Tatarkiewicz K., Belanger P., Gu G., Parkes D., Roy D., (2013). No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab 15, 417-26.
40. Tatarkiewicz K., Smith P. A., Sablan E. J., Polizzi C. J., Aumann D. E., Villescaz C., Hargrove D. M., Gedulin B. R., Lu M. G., Adams L., Whisenant T., Roy D., Parkes D. G., (2010). Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 299, E1076-86.
41. Tripathy N. R., Basha S., Jain R., Shetty S., Ramachandran A., (2008). Exenatide and acute pancreatitis. J Assoc Physicians India 56, 987-88.
42. Vora J. P., Zimsen S. M., Houghton D. C., Anderson S., (1996). Evolution of metabolic and renal changes in the Zdf/Drt-Fa rat model of type II diabetes. J Am Soc Nephrol 7, 113-17.
43. Vrang N., Jelsing J., Simonsen L., Jensen A. E., Thorup I., Soeborg H., Knudsen L. B., (2012). The effects of 13 Wk of liraglutide treatment on endocrine and exocrine pancreas in male and female Zdf rats: A quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab 303, E253-64.
44. Wesson R. N., Sparaco A., Smith M. D., (2008). Chronic pancreatitis in a patient with malnutrition due to anorexia nervosa. J Pancreas Online 9, 327-31.
45. Wild D., Behe M., Wicki A., Storch D., Waser B., Gotthardt M., Keil B., Christofori G., Reubi J. C., Macke H. R., (2006). [Lys40(Ahx-Dtpa-111in)Nh2]Exendin-4, a very promising ligand for glucagon-like peptide-1 (Glp-1) receptor targeting. J Nucl Med 47, 2025-33.
46. Xu G., Stoffers D. A., Habener J. F., Bonner-Weir S., (1999). Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-76.
47. Zhou J., Montrose-Rafizadeh C., Janczewski A. M., Pineyro M. A., Sollott S. J., Wang Y., Egan J. M., (1999). Glucagon-like peptide-1 does not mediate amylase release from Ar42j cells. J Cell Physiol 181, 470-78.